# Life Sciences Industry Overview

CHICAGOLAND & MAJOR U.S. MARKETS

Q4 2019





#1
Boston-Cambridge

San Francisco Bay Area

#3
San Diego


Chicago
(6th largest by employees)

**Considerations** 

Size of Lab Inventory Long-Term
Growth in
Employment

Number and Concentration of Key Scientists Size of Funding Sources

# Market Overview Life Sciences



# Chicagoland Life Sciences: How Big Is It?

\$98.6B

in Economic Output 85,000+

Life Sciences Industry Direct Employees 3,700+

**Establishments** 

source: TEConomy/BIO 2018

185

Pharma Companies<sup>1</sup> 550

Global Medical
Device & Diagnostics
Companies<sup>1</sup>

95

Hospitals & Medical Centers

30+

Leading Contract Research
Organization &
Contract Manufacturing
Organization Companies

<sup>&#</sup>x27;Source: TEConomy/BIO 201

<sup>&</sup>lt;sup>2</sup> Source: American Hospital Association, American Medical Association, Illinois
Hospital Association Truven Health Analytics, U.S. News and World Report

# Chicago's Life Sciences Ecosystem Development

### Select Labor Summary

# Jobs included

- + Biochemists & Biophysicists
- + Biological & Materials Scientists
- + Microbiologists
- **+** Biological Technicians
- + Chemists
- Medical And Clinical Laboratory Technologists & Technicians
- Biomedical, Electrical, Chemical,
   Mechanical & Materials Engineers
- **+** Computer Programmers
- Applications & SystemsSoftware Developers
- + Statisticians

2018
Job Counts

106,250

Boston-Cambridge

191,340

San Francisco Bay Area

86,470

Chicago

51,940

San Diego

2018 Average Wages

\$103,080

Boston-Cambridge

\$130,005

San Francisco Bay Area

\$91,921

Chicago

\$97,324

San Diego



MONTHLY
PHARMA EMPLOYEE
TURNOVER RATE



5.3% turnover



3.9% turnover



5.9% turnover



3.5% turnover

Boston has a 51% higher turnover rate than Chicago

**Key Universities** with Leading Bioscience Programs

## Cost of Living Index



#### Abbott A Promise for Life teva OAKORN abbvie Density of Partners NarMEDium PharMEDium OMRON: COVIDIEN Pharmaceuticals **M**elinta (Takeda) Baxter avešis Luminex. FRESENIUS KABI ZIMMER BIOMET sysmex 18.9M SF TATE N LYLE SIEMENS MEDLINE Occupied SAGENT APTINYX **Cardinal**Health ThermoFisher exiCure Celgene xeris Carol Stream

molex

**⇔** BD

Seurat

tp


"TEMPUS

Pixys

FITERUM herapeutics

Actavis + PURATA
PIONEER. Pix

# Life Sciences HQ/Lab Bifurcation Examples





# Dedicated Partners

- + Direct Access to Top Global Life Sciences Companies/ Lab Developers
- + Best Practice Insights & Scalable Global Platform
- + Unparalleled Expertise in Chicagoland Lab and R&D Space
- + Connections to Government, University & Community Partnerships



## CBRE's Unmatched Life Science Experience

**CBRE National Life Science Practice** 



of the world's top 10
pharmaceutical companies
partner with CBRE

750
Transactions
Over 5 Years

Advisory & Transaction
Services Professionals

130 M square feet managed for

square feet managed for Life Sciences clients 220

**Life Sciences Clients** 

Global strength in over

80 countries



## Global Life Science Connectivity

























Celanese



































# Thank You **CBRE**

CBRE © 2019 All Rights Reserved. All information included in this letter/proposal pertaining to CBRE, Inc.—including but not limited to its operations, employees, technology and clients—is proprietary and confidential and supplied with the understanding that such information will be held in confidence and not disclosed to any third party without CBRE's prior written consent. This letter/proposal is intended solely as a preliminary expression of general intentions, is for discussion purposes only, and does not create any agreement or obligation by CBRE to negotiate or continue negotiations. CBRE shall have no contractual obligation with respect to the matters referred to herein unless and until a definitive, fully-executed agreement has been delivered by the parties. Prior to delivery of a definitive executed agreement, and without any liability to the other party, either party may (1) propose different terms from those summarized herein, (2) enter into negotiations with other parties and/or (3) unilaterally terminate all negotiations with the other party hereto. / CBRE and the CBRE logo are service marks of CBRE, Inc. All other marks displayed on this document are the property of their respective owners, and the use of such logos does not imply any affiliation with or endorsement of CBRE.